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Using circular diehroism, this study investigated the secondary structure ofthe influenza A M2 transmembrane domain. When reconstituted into 
1,2-dioleoyl-stl-glyc~ro-3-phosphecholine liposol S, the M2 transmembrane domain was found to adopt a predominantly a-helical secondary 
structure which was unaffected byboth temperature and the addition of l-aminoadamantane hydrochloride. Reeonstitution nto 1,2.dioleoyl-sn- 
glycero.3.phosphoglycerol liposomes resulted ina marked ecrease in helical content. 
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1. INTRODUCTION 
The influenza A virus M2 protein has recently been 
the focus of extensive research. This protein is expressed 
on the cell surface during viral synthesis [1] and has been 
identified in viral particles [2]. It is a disulphide-bonded 
homotetramer [3] of 97 amino acids and is important 
during two separate phases of the cell cycle [4]. Immedi- 
ately after viral endocytosis, and concomitant with pH- 
induced fusion between the endosomal and viral mem- 
branes, mediated by hemagglutinin (HA) [5], M2 is 
thought to conduct protons into the interior of the virus, 
leading to uncoating, the release of ribonueleoprotein 
from the matrix protein (M1), and eventual nuclear 
infection [6]. When HA is transported to the cell surface 
in post-Golgi vesicles [7], M2 may also facilitate influ- 
enza synthesis and assembly by countering any vesicu- 
lar acidification. The relative importance of these 
events, which occur at different stages of the infectivity 
cycle, may depend on the particular viral strain [4]. 
Amantadine (l-aminoadamantane hydrochloride), the 
only registered rug used in the prophylaxis and treat- 
ment of influenza int~etions, is thought o operate by 
impeding proton flow during these events, however, it 
is not yet clear if the mechanism of this action involves 
an alteration in the secondary structure of the mem- 
brane-spanning domain or physical blockade. Impor- 
tantly, influenza A is thought o become resistant o 
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amantadine via single amino acid substitutions in the 
membrane-spanning domain of M2 [8]. 
Regarding the thesis that M2 orchestrates proton 
flow, it has recently been shown that, when expressed 
in Xenopus laevis oocytes, it has an associated ion chan- 
nel activity selective for monovalent cations [9]; using 
a two-electrode voltage-clamp rocedure the Pinto 
study observed Na ÷ and K * currents. In addition, a 
further electrophysiologica.i study directly identified 
proton translocation when the transmembrane domain 
of M2 was incorporated into single-channel, voltage- 
clamped, planar lipid bilayers [I0]. Both studies re- 
ported current negation upon addition of amantadine. 
The premise that membrane-spanning re ions are 
often cx-helical is generally based on theoretical predic- 
tions and observations of such in bacterial photosyn- 
thetic reaction centres [11-I3]. In addition, when the 
M2 transmembrane domain is modelled as an a-helix 
the residues which are substituted in amantadine-resis- 
tent mutants all appear on the same face of the helix 
[14]. Thus it is an attractive assumption that the M2 
transmembrane domain is s-helical, however, several 
caveats exist. An amantadine-resistant influenza virus 
has been isolated that contains a proline substitution i
the transmembrane domain, which is not usually 
thought o be compatible with a helical conformation 
[8]. In addition, Pinto et al. [9] observed that deletion of 
four transmembrane residues and addition of one extra 
residue still permitted ion channel activity. 
The present study describes an investigation of the 
secondary structure of the native influenza A M2 trans- 
membrane domain, and the influence of amantadine at
different concentrations, using circular dichroism (CD), 
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The results are discussed in terms of the recent electro- 
physiological data available concerning the mode of 
action of the M2 protein. 
2. EXPERIMENTAL 
In order to investigate the secondary structure of the inllucnza A 
M2 transmcmbrane domain, a synthetic 25 residue peptidc (squence: 
SSDPLVVAASlIGlLHLILWlLDRL), corresponding to the pre- 
dicted transmembrnne s quence common to several strains of influ- 
enza A [ 151, was incorporated into I ,2-dioleoyl-sn.glycero-3.phospho- 
choline (DOPC) liposomcs [IG] and examind using CD. The pcptidc 
was synthesized in the MRC Cellular Immunology Unit, Oxford. UK, 
purified by reverse-phase HPLC and subsequently sequcnccd in the 
WelMet Unh, University of Edinburgh, UK. The lipid was chosen for 
this study because phosphatidylcholine is the most common phospho- 
lipid headgroup in mammulian systems and oleic acid represents he 
most frequently occurring fatty acyl chain. The possible effects of 
temperature, addition of amantadine, and liposomnl ipid type used, 
were also investigated. M2 was also reconstituted into 1,2-dioleoyl-srr- 
glyccro3-phosphoglycerol (DOPG) liposomce. 
CD spectra were recorded on a JASCO J-600 speclropolarimcter; 
analysis of the spectra in terms of secondary structure content was 
undcrtakcn using the CONTIN procedure of Provcnchcr and 
Glockner [17]. the methods ofChange al. [la] andofSiegelcta1, [19]. 
The liposomcs were prepared in a 10 mM Tris-HCI, 0. I mM EDTA 
buffer system, pH 7.4. Two concentrations ofamantadinc were added 
to the recqnstitutcd liposomes, 4and 12~gIml. These were designated 
low and hr,:h concentration, respectively. All chemicals were supplied 
by Sigma Chemical Co., UK. 
Liposomal and control protein concentrations were determined col- 
orimetrically following the Lowry modification of Markwcll ct al. [20], 
using bovine serum albumin as standard. 
3. RESULTS AND DISCUSSION 
The far UV CD spectrum at 20°C of the M2 trans- 
membrane peptide incorporated into DOPC liposomes 
is shown in Fig. 1. Under these conditions, satisfactory 
data could be obtained down to 200 nm; below this 
wavelength, the noise levels precluded accurate meas- 
urements of ellipticity. The spectrum shows the charac- 
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Pig. 1. Far ‘JVCD sptr3 o!'P.Q peptide incorporated Into liposomes. 
Spectrn were recorded at 20°C in a cell of path length 0.02 cm (-) 
DOPC liposomes; (- - -) DOPG liposomes. The liposomal peptide 
concentrations were 0.16 and 0.27 mg/ml, respectively. 
teristic double minima at 223 nm and 209 nm of a- 
helices [18]. Estimates of 92, 79 and 100% a-helix were 
obtained using the methods of Provencher and 
Glbckner [17], Chang et al. [18] and Siegel et al. [19], 
respectively. Although the exact values of these esti- 
mates hould be treated with caution, in view of the fact 
that data could only be collected down to 209 nm in- 
stead of 190 nm, which is preferred [17,18], it is clear 
that under these conditions the M2 peptide exists 
largely, if not completely, in an a-helical form. In addi- 
tion, estimates of helix approaching 100% have been 
obtained both when M2 peptide is dissolved in 0.4% 
(w/v) sodium dodecyl sulphate (SDS) and 50% (v/v> 
2,2,2-trifluoroethanol (TFE) (see Table I). These sol- 
vents maximize possible secondary structure conforma- 
tion. Such results are in direct contra-st o those ob- 
tained when M2 is dissolved in buffer. In aqueous olu- 
tion, the M2 peptide did not apparently adopt any sta- 
ble secondary structure; the low value of the molar el- 
lipticity at 225 nm (Table 1) is typical of a random coil. 
The DOPC liposomal measurements were repeated at 
37”C, and no change was observed in the spectrum 
when compared with the 20°C data. 
On addition of amantadine to the liposomes, to give 
final concentrations of 4 or 12 pg/ml, there were no 
significant changes in the CD spectra (see the molar 
ellipticity values in Table I). Both low and high drug 
concentrations were used in order to examine any possi- 
ble concentration dependence [21]. These results are sig- 
nificant in that they clearly demonstrate that amanta- 
dine itself has no discernable ffect upon the helical 
nature of the L12 peptide, as was previously mooted 
[22]. This, along with recent findings that amantadine 
does indeed inhibit ion flow through M2 [9,10], aug- 
ments the thesis that the efficacy of amantadine is due 
to its channel-blocking abilities and not to any confor- 
mational interference. 
Table I 
Values OF molar ellipticiliea t 225 nm for M2 pptidc incorporated 
into liposomes 
- 
Sample Ellipdcity at 225 nm 
(degcm’.dmol-‘) 
M2 ppdde in DOPC liposomes (2OOC) 
M2 pcptidc in DOPC liposomcs (37°C) 
M? ppddc in DOPC IiposomLz (2O’C) plus 
amnntadine (4 pg/ml) 
-22,260 
-21.660 
-21.970 
M? ppdde in DOPC liposomes (2O’C) plus 
amantadinc (12 AS/ml) 
-23.190 
M? peptidc in DOPG liposomes (20°C) -11,430 
M2 pepdde in 0.4% (w/v) SDS -22,840 
M2 peptide in 50% (v/v) TFE -24,440 
M2 peptide in buffer (2O’C) -700 
Molar clhpticity values were c3lcul3tcd from the observed CD spectra 
using 9 VLIIUC oT I IO for the mean residue weight. The error in the 
ellipticity values is Lztirnatcd to be f 5%. 
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The M2 peptide incorporated into DOPG liposomes 
showed a considerably reduced CD spectruln (Fig. 1 
and Table I), Analysis of this spectrum by the CONTIN 
procedure [17] yielded unacceptably high errors of esti- 
mates of secondary structure; the methods of Chang et 
al. [18] and of Siegel et el. [19] yielded values of 41 and 
47% a-helix, respectively, in accord with the reduced 
values of the ellipticity at 225 nm (Table I). These exper- 
iments demonstrate a relationship between bilayer com- 
position and the secondary structure of the peptide. 
Epand et al. [23] have demonstrated that the helical 
content of salmon caleitonin is dependent on the per- 
centage of phosphatidylglycerol; altering the charge 
state of the membrane alters the helical content of the 
hormone. A similar phenomenon may also be found 
with peptide toxins where, for example, cardiotoxin and 
melittin are able to modulate lipid surface curvature and 
polymorphism in a lipid-specific manner [24]. 
In summary, the transmembrane domain of M2 
adopts an s-helical conformation in DOPC liposomes, 
and this structure is not affected by the presence of the 
drug, amandatine. In view of recent developments in the 
study of M2 protein, these results answer the questions 
raised regarding M2 in bilayers [9,14,22], and help to 
explain its structural mechanism. 
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